Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC36 oral tablets, its first oral amylin receptor peptide agonist, for clinical development. Ascletis expects to submit an ...
Many drugs are poorly water-soluble and lipophilic (fat-loving), and both pose challenges to bioavailability. As you’re probably aware, the human body, including the GI tract, is mostly water, so if a ...
A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: Interim data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results